| ZyVersa Therapeutics, Inc. (ZVSA) | |||||||||||||||||||||||||||||||||||||||||||||||||
| Q4-CY2025 | Q3-CY2025 | Q2-CY2025 | Q1-CY2025 | Q4-CY2024 | Q3-CY2024 | Q2-CY2024 | Q1-CY2024 | Q4-CY2023 | Q3-CY2023 | Q2-CY2023 | Q1-CY2023 | Q4-CY2022 | Q3-CY2022 | Q2-CY2022 | Q1-CY2022 | Q4-CY2021 | Q3-CY2021 | Q2-CY2021 | Q1-CY2021 | Q4-CY2020 | Q3-CY2020 | Q2-CY2020 | Q1-CY2020 | Q4-CY2019 | Q3-CY2019 | Q2-CY2019 | Q1-CY2019 | Q4-CY2018 | Q3-CY2018 | Q2-CY2018 | Q1-CY2018 | Q4-CY2017 | Q3-CY2017 | Q2-CY2017 | Q1-CY2017 | Q4-CY2016 | Q3-CY2016 | Q2-CY2016 | Q1-CY2016 | Q4-CY2015 | Q3-CY2015 | Q2-CY2015 | Q1-CY2015 | Q4-CY2014 | Q3-CY2014 | Q2-CY2014 | Q1-CY2014 | Q4-CY2013 | |
| Balance Sheet Date | 2025-Sep-30 | 2025-Jun-30 | 2025-Mar-31 | 2024-Dec-31 | 2024-Sep-30 | 2024-Jun-30 | 2024-Mar-31 | 2023-Dec-31 | |||||||||||||||||||||||||||||||||||||||||
| Fiscal Period | Q3-FY2025 | Q2-FY2025 | Q1-FY2025 | Q4-FY2024 | Q3-FY2024 | Q2-FY2024 | Q1-FY2024 | Q4-FY2023 | |||||||||||||||||||||||||||||||||||||||||
| Price to Sales | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Price to Book | - | .53x | .19x | .31x | .35x | .34x | .51x | ||||||||||||||||||||||||||||||||||||||||||
| Price to Earnings | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Price to Unlevered FCF | - | - | - | - | - | - | - | ||||||||||||||||||||||||||||||||||||||||||
| Debt to Asset Ratio | 12.27x | .69x | .61x | .59x | .64x | .56x | .48x | .50x | .16x | ||||||||||||||||||||||||||||||||||||||||
| Current Ratio | .08x | .04x | .18x | .15x | .03x | .06x | .30x | .33x | .78x | ||||||||||||||||||||||||||||||||||||||||